Recent Finacing
Recent Raise
NeuExcell Therapeutics develops an AAV-based, in‑situ astrocyte-to-neuron gene therapy platform that delivers neural transcription factors to regenerate functional neurons for treatment of neurodegenerative diseases and CNS injuries.
